Ibrance vs Dupixent
Side-by-side drug price comparison from Medicare Part D data
Verdict
Dupixent costs 74% less per claim than Ibrance ($2819.00 vs $10816.00). Ibrance has a generic alternative available. Total Medicare spending: Ibrance at $4.5B vs Dupixent at $4.4B.
| Metric | Ibrance | Dupixent |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $10,816 | $2,819* |
| Total Medicare Spending Total Medicare Part D spending on this drug | $4.5B | $4.4B |
| Total Claims | 418,000 | 1,560,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | -5.6%* | 35.2% |
| Generic Available | Yes | No |
| Condition | Cancer | Autoimmune Diseases |
| Total Beneficiaries | 36,000 | 245,000 |
Dupixent costs 74% less per claim than Ibrance ($2819.00 vs $10816.00). Ibrance has a generic alternative available. Total Medicare spending: Ibrance at $4.5B vs Dupixent at $4.4B.
Explore More
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both Ibrance and Dupixent. What follows is the interpretation — which specific axes carry the most weight for Ibrance versus Dupixent, and which differences are large enough to influence a real decision.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.